Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 59 for your search:
Cancer Type:
Stomach (gastric) cancer
Stage/Subtype of Cancer:
stage IV gastric cancer
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EGF110656
, EGF110656-TRIO-CIRG 013, NCT00680901
2.
A Safety and Efficacy Study in Patients With Gastric Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
TPU S-1301
, NCT00400179
3.
Intraperitoneal Floxuridine in Gastric Carcinoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2150
, NCT00058916
4.
Phase I/II Study of Erlotinib Hydrochloride and Cetuximab in Patients With Advanced Gastrointestinal, Head and Neck, Non-Small Cell Lung, or Colorectal Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
VU-VICC-GI-0622
, VICC-GI-0622, 6980, NCI-6980, NCT00397384
5.
Low Dose Radiation Therapy as Chemosensitizer in GI/ Ovarian Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
H-22706
, NCT00390182
6.
Evaluation of Single Session Stereotactic Body Radiotherapy
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2005-0445
, NCT00492817
7.
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CTCT 06-11
, NCT00493883
8.
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
Phase:
Phase II, Phase I
Type:
Supportive care, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
ID02-446
, NCT00508443
9.
Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
2004-0290
, NCT00526110
10.
An Open-Label, Single-Center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AT-101-CS-102
, NCT00561197
11.
Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 82
Sponsor:
Other
Protocol IDs:
Pro00002207
, SPS 151596, NCT00578071
12.
Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil in Patients With Metastatic or Unresectable Stomach or Gastroesophageal Junction Adenocarcinoma or Other Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NU-0412
, SANOFI - AVENTIS-NU0412, NU 04I2, NU-948-006, NCT00711243
13.
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
20060317
, NCT00719550
14.
Phase II Study of Intrahepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion in Patients With Unresectable Primary or Metastatic Liver Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-04-C-0273
, NCI-6332, DELCATH-G990039, NCT00096083
15.
Phase II Study of Bevacizumab, Oxaliplatin, and Docetaxel in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
WSU-D-2840
, UMCC-2005-052, AVENTIS-WSU-D-2840, NCT00217581
16.
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
05-113
, NCT00130689
17.
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
3G-03-5
, NCT00183872
18.
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
3G-03-4
, NCT00183898
19.
Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
No age specified
Sponsor:
Other
Protocol IDs:
HSC-MS-04-259
, NCT00178698
20.
Docetaxel and Oxaliplatin in Gastric Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
DOCOX_C_00082
, EudraCT # : 2005-005464-92, NCT00382720
21.
Phase II Study of Cetuximab, Cisplatin, and Irinotecan Hydrochloride in Patients With Irinotecan Hydrochloride- and Cisplatin-Refractory Metastatic Esophageal, Gastroesophageal Junction Cancer, or Gastric Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-06095
, NCT00397904
22.
Phase II Study of Docetaxel, Cisplatin, Fluorouracil, Leucovorin Calcium, and Bevacizumab in Patients With Locally Recurrent, Unresectable, or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-06096
, NCT00403468
23.
Phase II Study of Floxuridine, Leucovorin Calcium, Oxaliplatin, and Docetaxel as First-Line Treatment in Patients With Unresectable Stage IV Gastric Adenocarcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
EPROST-20040005
, EPROST-20040005, SCCC-2003150, SCCC-20050983, AVENTIS-SCCC-2003150, SCCC-20040005, NCT00448682
24.
Xelox (Xeloda + Oxaliplatin) and Avastin for Metastatic Esophagogastric Adenocarcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
8797
, NCT00447330
25.
Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
CINJ-3330
, NCT00161187
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
